Market revenue in 2023 | USD 321.3 million |
Market revenue in 2030 | USD 836.8 million |
Growth rate | 14.7% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 56.55% in 2023. Horizon Databook has segmented the Italy cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Italy contributed to 14.2% of the global cell and gene therapy clinical trials market in 2021. In Italy, Cell and Gene Therapy Clinical Trials conducted are frequently funded by pharmaceutical companies acting as trial sponsors.
However, investigator-initiated studies are very common in Italy. In such cases, pharmaceutical firms may provide financial support. Italy is working from many years to become a major player in the clinical studies owing to its top-level research institutions & hospitals present in the country.
As per Farmindustria, around 20% of the Cell and Gene Therapy Clinical Trials among Europe are run in Italy. Italy also ranks first for the number of valuebased, Management Entry Agreements (MEAs) signed with pharmaceutical companies. Italy’s biotech companies typically focus on cancers and other diseases, including infectious, cardiovascular, neurological, and inflammatory diseases.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Italy cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account